Evolus, Inc. (0K16.L)
USD 11.39
(0.03%)
USD 11.39
(0.03%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -49.23 Million USD | 37.29% |
| 2022 | -57.57 Million USD | 9.49% |
| 2021 | -63.61 Million USD | 7.4% |
| 2020 | -68.69 Million USD | 27.52% |
| 2019 | -94.78 Million USD | -105.42% |
| 2018 | -46.14 Million USD | -293.5% |
| 2017 | -11.72 Million USD | 41.27% |
| 2016 | -19.96 Million USD | 35.55% |
| 2015 | -30.98 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -7.34 Million USD | -44.51% |
| 2024 Q2 | -6.09 Million USD | 16.98% |
| 2023 FY | -36.1 Million USD | 37.29% |
| 2023 Q2 | -15.11 Million USD | -45.48% |
| 2023 Q1 | -10.39 Million USD | -17.72% |
| 2023 Q3 | -13.44 Million USD | 11.1% |
| 2023 Q4 | -5.08 Million USD | 62.19% |
| 2022 Q2 | -21.34 Million USD | -51.06% |
| 2022 Q4 | -8.82 Million USD | 47.08% |
| 2022 Q3 | -16.68 Million USD | 21.86% |
| 2022 FY | -57.57 Million USD | 9.49% |
| 2022 Q1 | -14.13 Million USD | 21.66% |
| 2021 Q1 | 8.01 Million USD | 107.42% |
| 2021 Q2 | -15.3 Million USD | -290.94% |
| 2021 Q3 | -19.12 Million USD | -24.96% |
| 2021 Q4 | -18.04 Million USD | 5.66% |
| 2021 FY | -63.61 Million USD | 7.4% |
| 2020 Q2 | -18.88 Million USD | -8.58% |
| 2020 FY | -68.69 Million USD | 27.52% |
| 2020 Q3 | -8.76 Million USD | 53.62% |
| 2020 Q4 | -108.02 Million USD | -1133.17% |
| 2020 Q1 | -17.39 Million USD | -38.68% |
| 2019 Q3 | -25.13 Million USD | 30.17% |
| 2019 FY | -94.78 Million USD | -105.42% |
| 2019 Q4 | -12.54 Million USD | 50.1% |
| 2019 Q2 | -35.99 Million USD | -42.46% |
| 2019 Q1 | -25.26 Million USD | -102.02% |
| 2018 Q2 | -16.1 Million USD | -166.34% |
| 2018 FY | -46.14 Million USD | -293.5% |
| 2018 Q4 | -12.5 Million USD | -8.87% |
| 2018 Q3 | -11.48 Million USD | 28.64% |
| 2018 Q1 | -6.04 Million USD | -111.51% |
| 2017 Q2 | -2.27 Million USD | 42.8% |
| 2017 Q3 | -2.61 Million USD | -14.99% |
| 2017 Q1 | -3.97 Million USD | -7.34% |
| 2017 FY | -11.72 Million USD | 41.27% |
| 2017 Q4 | -2.85 Million USD | -9.25% |
| 2016 Q4 | -3.7 Million USD | 10.83% |
| 2016 Q2 | -6.05 Million USD | 0.0% |
| 2016 Q3 | -4.15 Million USD | 31.36% |
| 2016 Q1 | -6.05 Million USD | 0.0% |
| 2016 FY | -19.96 Million USD | 35.55% |
| 2015 FY | -30.98 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 70.899% |
| Dynavax Technologies Corporation | -37.02 Million USD | -32.962% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -834.39% |
| Perrigo Company plc | 151.9 Million USD | 132.411% |
| Illumina, Inc. | -1.06 Billion USD | 95.394% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 100.718% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 89.31% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.65% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 102.49% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 55.492% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 101.217% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -10.222% |
| Waters Corporation | 817.67 Million USD | 106.021% |
| Biogen Inc. | 1.29 Billion USD | 103.796% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 82.032% |
| Adicet Bio, Inc. | -152.03 Million USD | 67.618% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 59.477% |
| bluebird bio, Inc. | -244.26 Million USD | 79.844% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 68.352% |
| FibroGen, Inc. | -281.81 Million USD | 82.53% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 103.647% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -9.219% |
| Homology Medicines, Inc. | -48.25 Million USD | -2.027% |
| Geron Corporation | -193.94 Million USD | 74.615% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 82.552% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 33.011% |
| Myriad Genetics, Inc. | -123.7 Million USD | 60.2% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 51.171% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 90.446% |
| Zoetis Inc. | 3.06 Billion USD | 101.604% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -2.143% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 104.528% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 125.32% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 101.143% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -25.745% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 86.082% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 82.162% |
| Verastem, Inc. | -92.08 Million USD | 46.535% |
| Nektar Therapeutics | -137.42 Million USD | 64.175% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 78.763% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 49.43% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 81.617% |
| OPKO Health, Inc. | -157.02 Million USD | 68.646% |
| Exelixis, Inc. | 170.88 Million USD | 128.811% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 119.623% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 145.891% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 11.699% |
| uniQure N.V. | -282.87 Million USD | 82.595% |
| Imunon, Inc. | -21.03 Million USD | -134.104% |
| Blueprint Medicines Corporation | -486.27 Million USD | 89.876% |
| Insmed Incorporated | -709.62 Million USD | 93.062% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 114.584% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 87.424% |
| TG Therapeutics, Inc. | 20.63 Million USD | 338.613% |
| Incyte Corporation | 620.52 Million USD | 107.934% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 93.222% |